Hemorrhagic transformation in focal cerebral ischemia: Influence of time to artery reopening and tissue plasminogen activator

被引:30
作者
Fagan, SC
Garcia, JH
机构
[1] Wayne State Univ, Coll Pharm & Allied Hlth Profess, Detroit, MI 48202 USA
[2] Henry Ford Hosp, Dept Pharm Serv, Detroit, MI 48202 USA
[3] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA
[4] Henry Ford Hosp, Dept Pathol Neuropathol, Detroit, MI 48202 USA
来源
PHARMACOTHERAPY | 1999年 / 19卷 / 02期
关键词
D O I
10.1592/phco.19.3.139.30932
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We used an adaptation of a well-established rat model of middle cerebral artery occlusion (MCAO) that is both minimally invasive and reproducible to determine the effects of time to reperfusion and administration of tissue plasminogen activator (t-PA) on the development of hemorrhagic transformation (HT) in a rat model of acute stroke. Animals were randomized to receive either t-PA 10 mg/kg (29 rats) or an equal volume of saline (29 rats) over 20 minutes, beginning 5 minutes before reperfusion. Time to artery reopening varied between 1 and 24 hours after MCAO in both groups. At 18-24 hours after ischemia, the animals were sacrificed and their brains were preserved for analysis of HT. Logistic regression was used to determine the influence of time on HT risk and calculate the time at which 50% of animals developed HT (HT50%). At 24 hours, HT was present in 17 of 29 animals in each group and was significantly influenced by the time of artery reopening: 3 (15%) of 20 animals reperfused less than 3 hours after onset of ischemia and 32 (84%) of 38 reperfused 3 or more hours after the onset of ischemia (p<0.001). There was no difference in HT50% between groups. Time to artery reopening is an important determinant of HT risk in this model of cerebral ischemia. This model may have utility in developing strategies to reduce HT formation after thrombolytic therapy in patients with acute stroke.
引用
收藏
页码:139 / 142
页数:4
相关论文
共 25 条
[21]   TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE [J].
MARLER, JR ;
BROTT, T ;
BRODERICK, J ;
KOTHARI, R ;
ODONOGHUE, M ;
BARSAN, W ;
TOMSICK, T ;
SPILKER, J ;
MILLER, R ;
SAUERBECK, L ;
JARRELL, J ;
KELLY, J ;
PERKINS, T ;
MCDONALD, T ;
RORICK, M ;
HICKEY, C ;
ARMITAGE, J ;
PERRY, C ;
THALINGER, K ;
RHUDE, R ;
SCHILL, J ;
BECKER, PS ;
HEATH, RS ;
ADAMS, D ;
REED, R ;
KLEI, M ;
HUGHES, S ;
ANTHONY, J ;
BAUDENDISTEL, D ;
ZADICOFF, C ;
RYMER, M ;
BETTINGER, I ;
LAUBINGER, P ;
SCHMERLER, M ;
MEIROSE, G ;
LYDEN, P ;
RAPP, K ;
BABCOCK, T ;
DAUM, P ;
PERSONA, D ;
BRODY, M ;
JACKSON, C ;
LEWIS, S ;
LISS, J ;
MAHDAVI, Z ;
ROTHROCK, J ;
TOM, T ;
ZWEIFLER, R ;
DUNFORD, J ;
ZIVIN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1581-1587
[22]  
MOULIN T, 1993, EUR NEUROL, V34, P64
[23]  
OKADA Y, 1989, STROKE, V20, P589
[24]   DOSE-RESPONSE OF RT-PA AND ITS COMBINATION WITH ASPIRIN IN A RAT EMBOLIC STROKE MODEL [J].
OVERGAARD, K ;
SEREGHY, T ;
PEDERSEN, H ;
BOYSEN, G .
NEUROREPORT, 1992, 3 (10) :925-928
[25]   QUANTAL BIOASSAY AND STROKE [J].
ZIVIN, JA ;
WAUD, DR .
STROKE, 1992, 23 (05) :767-773